Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience (TWST) entered an agreement with Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly, to provide antibody characterization data services that support TuneLab’s antibody prediction models, including AbLab.
Participating companies using TuneLab will be able to order antibody services from Twist via TuneLab’s preferred Twist protocols to generate high-quality wet lab data that can train and refine AI models. This connects Twist’s high-throughput experimental capabilities with Lilly’s AI-enabled discovery ecosystem, aiming to help researchers more efficiently down-select antibody candidates and contribute data back into TuneLab for federated model training.
Twist Bioscience (TWST) will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, at 1:25 p.m. Eastern Time in New York City.
The session with CEO Emily M. Leproust, Ph.D., and CFO Adam Laponis will be webcast live via the Investor Calendar page of Twist Bioscience’s investor relations website. A replay of the event will be archived and available for 30 days after the live presentation.
Twist Bioscience (Nasdaq: TWST) priced an upsized underwritten public offering of 3,125,000 common shares at $96.00 per share, for expected gross proceeds of $300.0 million before fees and expenses. The company granted underwriters a 30-day option to purchase up to 468,750 additional shares at the same public price, less underwriting discounts and commissions.
The offering is expected to close on August 6, 2026, subject to customary conditions. According to Twist, net proceeds plus existing cash will fund R&D investments, manufacturing capacity expansion, product offerings, and general corporate purposes. Goldman Sachs, William Blair, Leerink Partners and Guggenheim Securities are joint book-running managers.
Twist Bioscience (Nasdaq: TWST) commenced a proposed underwritten public offering of $250.0 million of common stock and plans to grant underwriters a 30-day option to purchase up to an additional $37.5 million of shares. All shares will be sold by Twist.
The offering is subject to market and other conditions and may not be completed as outlined. According to Twist, net proceeds, together with existing cash and marketable securities, are intended to fund R&D investments, manufacturing capacity expansion, product offerings, and general corporate and working capital needs. Goldman Sachs, William Blair, Leerink Partners and Guggenheim Securities act as joint book-running managers.
Twist Bioscience (NASDAQ: TWST) announced that it will grant a total of 44,434 restricted stock units (RSUs) to 24 recently hired employees as employment inducement awards under its Amended and Restated Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
According to Twist, the inducement plan is used exclusively for individuals not previously employed by the company (or after a bona fide break), and is intended as a material inducement to join Twist. Portions of the RSUs vest over 48 months, either with 25% vesting at the one-year anniversary then 1/16 quarterly, or 1/16 vesting each quarter from the vesting commencement date, in each case subject to continued service.
Twist Bioscience (NASDAQ: TWST) reported its fiscal third quarter 2026 financial results for the period ended June 30, 2026, and directed investors to its Investor Relations Events and Presentations page for the full earnings report and investor presentation.
The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time on August 3, 2026, with access via advance telephone registration through its Investor Relations website and a webcast replay available for two weeks. Twist Bioscience also highlights its customizable synthetic biology and genomics solutions serving diagnostics, therapeutics, industrial, agriculture and research markets.
Twist Bioscience (NASDAQ: TWST) will release its fiscal 2026 third quarter financial results, for the period ended June 30, 2026, before market open on Monday, August 3, 2026. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time the same day to discuss results and provide a business update.
The earnings press release and webcast will be available through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Telephone participants must register via the Investor Relations website to receive dial-in details and a unique PIN. A webcast replay will be accessible for two weeks.
Twist Bioscience (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Adam Laponis will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026 at 10:00 a.m. CT in Chicago.
The presentation will be webcast live via the investor relations Investor Calendar page, with a replay available for 30 days.
Twist Bioscience (NASDAQ: TWST) announced inducement equity awards totaling 115,279 awards to 53 newly hired individuals: 101,931 restricted stock units (RSUs) and up to 13,348 performance stock units (PSUs).
RSUs largely vest over 48 months with standard 25% one-year cliff or quarterly vesting; PSUs vest based on performance metrics by fiscal 2027 (0%-150% payout range).
Twist Bioscience (NASDAQ: TWST) expanded its clonal genes portfolio with the early access launch of Complex Genes, enabling synthesis of sequences up to 7,000 base pairs and claiming acceptance of ~99.5% of clonal gene orders and ~99.9% of all DNA products. The offering targets AI-enabled drug discovery and nucleic acid therapeutics by producing difficult elements (repeats, inverted/long repeats, extreme GC) at commercial scale using its silicon-based synthesis platform and enhanced downstream processes.